Moderna’s COVID-19 Vaccine’s Pricing Disappoints Investors, But This Analyst Remains With the Bulls
mRNA vaccine maker Moderna (MRNA) has undoubtably been one of 2020’s success stories. One of the frontrunners in the race to develop a COVID-19 vaccine, investors have cheered each step of its candidate’s progress. While shares haven’t soared as majestically as those by some of its smaller sized peers, they have nevertheless appreciated by 243% so far this year.Yet, the company sparked confusion among investors last week after announcing that the US government has put an order in for 100 million doses of the company’s COVID-19 vaccine candidate mRNA-1273, for a total cost of $1.53 billion. As it turns out, …read more […]
